AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01459315
Drug: dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will take a GSK1349572 (dolutegravir) 50mg tablet by mouth once daily for 8 days. GSK1349572 concentrations will be measured in blood plasma, seminal fluid, rectal fluid, and rectal tissue over 24 hours after a single dose and over two 24 hour periods once steady state is reached. Blood plasma will be collected pre-dose and 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours after dosing. Each subject will also provide a total of 9 seminal and rectal fluid samples and have 2 rectal tissue biopsies performed pre-dose or at 1, 3, 6, 12, 18, or 24 hours after receiving single or multiple doses.
Trial: NCT02685293
Drug: GFF MDI (PT003)
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
Trial: NCT04201756
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ①Neoadjuvant treatment stage: the enrolled patients take afatinib at a dosage of 40mg per day, 8-16 weeks in total; and receive CT scan re-examination in the 4th/8th/12th post-therapy week.~②Surgical treatment stage: the patients who respond to alfatinib treatment (CR+PR) and the patients who do not respond to alfatinib therapy but could still undergo surgery (SD and PD) will receive radical lung lobectomy+systematic lymph node dissection.~③Adjuvant treatment stage: The CR, PR and SD patients who have been treated surgically will take alfatinib at a dosage of 40mg per day for at least 1 year. The SD and PD patients who could not receive operation and the PD patients who have received operation will be transferred into medical oncology or/and radiation oncology and receive comprehensive therapy (chemotherapy or/and radiotherapy, the regimen is designed by oncologist and radiologist)
Trial: NCT03227796
Drug: LEVI-04
RxNorm normalized name: Tritici aestivi levis semen
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEVI-04 intravenous infusion
Trial: NCT04870164
Drug: Ensovibep
RxNorm normalized name: Ensovibep
DrugBank: Ensovibep (DB19078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.
Trial: NCT02264574
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.
Trial: NCT02264574
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
Trial: NCT02264574
Drug: Chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
Trial: NCT02947711
Drug: E2027
RxNorm normalized name: Elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 50 mg capsules, once daily on Day 1 and Day 12
Trial: NCT02947711
Drug: Diltiazem ER
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM ER]
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 300 mg capsule, once daily on Days 7 through 24
Trial: NCT00088465
Drug: Intramuscular olanzapine depot
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
Trial: NCT00765661
Drug: Tacrolimus (Tacro™)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other Names:~Tacrolimus modified-release
Trial: NCT00908232
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
Trial: NCT00908232
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
Trial: NCT00908232
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg orally daily, days 1-14 for cycles 5 to 8
Trial: NCT00765661
Drug: Prograf
RxNorm normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus
Trial: NCT00448864
Drug: Ecallantide
RxNorm normalized name: Ecallantide
DrugBank: Ecallantide (DB05311)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00892229
Drug: Misoprostol (given buccally)
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
Trial: NCT00892229
Drug: Misoprostol (given vaginally)
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
Trial: NCT01600703
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin, 100mg, oral, single dose
Trial: NCT01371201
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sunitinib 37.5 mg per day
Trial: NCT03665506
Drug: Trifluridin/Tipiracil
DrugBank: Tipiracil (DB09343)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: QoL assessment
Trial: NCT02785055
Drug: Bupivacaine 0.05%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
Trial: NCT02785055
Drug: Hydromorphone 0.01mg/mL
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
Trial: NCT00185172
Drug: olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil oral tablets for 8 weeks
Trial: NCT02880033
Drug: deferiprone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: to test the action of deferiprone on lymphocytes from patients and controls ex vivo
Trial: NCT00090272
Drug: MK0826, ertapenem sodium
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00090272
Drug: Comparator: cefotetan
DrugBank: Cefotetan (DB01330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04531540
Drug: Butenafine HCl 1% (BAY1896425)
DrugBank: Butenafine (DB01091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.
Trial: NCT02737722
Drug: Bisphosphocin Nu-3
RxNorm normalized name: Bisphosphocin Nu-3
DrugBank: Bisphosphocin Nu-3 (DB16015)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02725099
Drug: Chewing Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 mg Chewing Ticagrelor
Trial: NCT02725099
Drug: Oral Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 mg oral Ticagrelor
Trial: NCT04620811
Drug: lirentelimab
RxNorm normalized name: Lirentelimab
DrugBank: Lirentelimab (DB16728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
Trial: NCT02170935
Drug: BIBR 1048 capsule
RxNorm normalized name: bibrocathol
DrugBank: Bibrocathol (DB13818)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00108524
Drug: Orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In addition to the low fat diet, Orlistat is taken 3 times daily.
Trial: NCT00174720
Drug: Ciclesonide (XRP1526)
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04355637
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: adding budesonide to standard of care for pneumonia in COVID19 positive patients
Trial: NCT01642940
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prasugrel 10mg/day
Trial: NCT01642940
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90mg twice a day
Trial: NCT02171455
Drug: Dabigatran etexilate low dose
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02171455
Drug: Dabigatran etexilate medium dose
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02171455
Drug: Dabigatran etexilate high dose
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00075231
Drug: Kaletra® (lopinavir/ritonavir)
DrugBank: Kale (DB14564)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04065009
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental drug will be administered intraperitoneally
Trial: NCT04065009
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intraperitoneally
Trial: NCT00006098
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03181451
Drug: Ferric Maltol
RxNorm normalized name: Ferric Maltol
DrugBank: Ferric maltol (DB15598)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
Trial: NCT01640275
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients randomized to the propofol arm of the study will receive general anesthesia with propofol
Trial: NCT01640275
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
Trial: NCT03178929
Drug: S-Adenosyl Methionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000mg, po
Trial: NCT02765165
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered once every 6 weeks in a 42-day cycle
Trial: NCT02689960
Drug: 100mg prednisone suppository
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vaginal administration of 100mg prednisone suppository (Rectodelt)
Trial: NCT01493648
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
Trial: NCT00505921
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
Trial: NCT00505921
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
Trial: NCT00505921
Drug: BCNU
RxNorm normalized name: BCNU
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/m2 IV over 1 hour on day -6
Trial: NCT00505921
Drug: Stem Cell Transplant
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem cell infusion on Day 0.
Trial: NCT00505921
Drug: Preparative Regimen for Allogenic Stem Cell Transplantation
RxNorm normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
Trial: NCT04019548
Drug: Cisplatin injection
RxNorm normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two therapeutic regimen allowed:~* Days 1 and 22 : cisplatin 100mg/m2 IV~* Days 1,8,15,22,29,36: weekly cisplatin 40 mg/m2 IV
Trial: NCT00505921
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
Trial: NCT00505921
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
Trial: NCT00505921
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 140 mg/m2 IV on day -1.
Trial: NCT00505921
Drug: Campath
RxNorm normalized name: Campath
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
Trial: NCT03295656
Drug: Sulfur hexafluoride lipid-type A microspheres
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced US imaging of the appendix
Trial: NCT02803047
Drug: Coppertone (BAY987516)
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation number - SR15-61-Z15-034).
Trial: NCT00505921
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 IV/day (days -6 to -4)
Trial: NCT01458626
Drug: mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mirtazapine 30mg QD
Trial: NCT01458626
Drug: paroxetine 20mg QD
RxNorm normalized name: paroxetine hydrochloride 20 MG
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: paroxetine 20mg QD
Trial: NCT01337934
Drug: Lactated Ringer
RxNorm normalized name: lactated ringers
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactated Ringer
Trial: NCT01337934
Drug: Albumin
RxNorm normalized name: Albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin 4%
Trial: NCT00772837
Drug: Omeprazole + placebo antibiotics
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week
Trial: NCT01134016
Drug: Antroquinonol
RxNorm normalized name: Antroquinonol
DrugBank: Antroquinonol (DB12326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.~Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded.
Trial: NCT02804178
Drug: ATR-101
RxNorm normalized name: Atr-101 free base
DrugBank: Nevanimibe (DB16254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125-1000 mg twice per week
Trial: NCT00529022
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75 mg/m\^2 Subcutaneous Injection or by vein Daily for 5 Days.
Trial: NCT00025402
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025402
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025402
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025402
Drug: hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00025402
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00529022
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/kg by mouth Daily for 7 days.
Trial: NCT00529022
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 2 by vein on Days 3 and 10 over 60 Minutes.
Trial: NCT02677246
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils \> 0,5x10(9)/L and chimerism ≥ 10% of donor origin.~Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.~Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.~Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab
Trial: NCT00707863
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg of Escitalopram by mouth once a day for 8 weeks
Trial: NCT04342169
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days
Trial: NCT01349725
Drug: ARRY-502
RxNorm normalized name: ARRY-502
DrugBank: ARRY-502 (DB16053)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; multiple dose, escalating
Trial: NCT04543344
Drug: Recifercept
RxNorm normalized name: Recifercept
DrugBank: Recifercept (DB17899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recifercept powder for solution for injection
Trial: NCT02860923
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03885830
Drug: Bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will be enrolled into this group if they are receiving bosutinib per standard of care. This is an observational study and no interventions will be made.
Trial: NCT00991276
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: capsules; 300 mg once-per-day; 4 weeks of treatment
Trial: NCT00991276
Drug: pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsules; 0.5 mg once-per-day; 4 weeks of treatment
Trial: NCT03720340
Drug: Recombinant Human Interleukin-11
RxNorm normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant Human Interleukin-11 was administed through respiratory tract.